Litigation Details for LTL Management LLC (Bankr. D.N.J. 2023)
✉ Email this page to a colleague
LTL Management LLC (Bankr. D.N.J. 2023)
| Docket | ⤷ Try a Trial | Date Filed | 2023-04-04 |
| Court | United States Bankruptcy Court, D. New Jersey | Date Terminated | |
| Cause | Assigned To | Michael B. Kaplan | |
| Jury Demand | Referred To | ||
| Patents | 10,010,507; 10,039,718; 10,052,314; 10,086,011; 10,106,548; 10,125,140; 10,143,693; 10,213,386; 7,094,781; 7,514,444; 8,013,113; 8,445,507; 8,476,284; 8,497,277; 8,697,711; 8,754,090; 8,754,091; 8,791,122; 8,802,689; 8,952,015; 8,957,079; 9,181,257; 9,284,280; 9,296,753; 9,439,906; 9,481,663; 9,539,218; 9,655,857; 9,725,455; 9,884,054; 9,987,261 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in LTL Management LLC
The small molecule drugs covered by the patents cited in this case are ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , and ⤷ Try a Trial .
Biologic Drugs cited in LTL Management LLC
The biologic drug covered by the patents cited in this case is ⤷ Try a Trial .
Details for LTL Management LLC (Bankr. D.N.J. 2023)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2023-07-19 | 1073 | Document | 73:17-74:2; 74:14-17. 112 Id. at 31:8 – 13. 113 June 28, 2023 A.M. Hr. Tr., 43:8-10.…Support Is Overstated and Plan Is Patently Unconfirmable ................................…of a plan because LTL’s plan23 (the “Plan”) is patently unconfirmable. Among other things, it would …” for the Plan has been misstated. The Plan is patently not confirmable under the Bankruptcy Code. The…Because Claimant Support Is Overstated and Plan Is Patently Unconfirmable 118. All the | External link to document |
| 2023-06-22 | 855 | Exhibit | ; 9,181,257; 9,296,753; 9,655,857; 9,725,455; 10,010,507; 10,106,548; and 10,125,140. In June 2019, Pharmacyclics…the Company. Patents The Company’s subsidiaries have made a practice of obtaining patent protection on…of matter patent expires in 2023. The latest expiring European composition of matter patent expires in… has an exclusive license to those patent families. The two patent families both expire in the United …licensed European patent expires in 2032. Janssen Biotech, Inc. owns a separate patent portfolio related | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
